Granted Patent
B2
US 12,508,278 · App. 18/205,229 · Granted Dec 30, 2025
Lipid nanoparticle compositions and methods of formulating the same
Inventors:
Meredith Packer (Waltham, MA); Dipendra Gyawali (East Walpole, MA); Serenus Hua (Cambridge, MA); Gabor Butora (Martinsville, NJ); Gregory John Mercer (Andover, MA)
Assignee:
ModernaTX, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Provided herein are compositions and methods of reducing adduct formation.
Claims (28)
1 . A method of administering mRNA to a subject, comprising administering to the subject a composition comprising a lipid nanoparticle comprising a mRNA, a phospholipid, a cholesterol, a PEG-lipid, and an ionizable lipid,
wherein the mRNA comprises an N1-methyl-pseudouridine (m1ψ) nucleobase,
wherein the ionizable lipid is selected from
wherein the phospholipid comprises one or more selected from 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-gly cero-phosphocholine (DMPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 Diether PC), 1-oleoyl-2 cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC), 1-hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC), 1,2-dilinolenoyl-sn-glycero-3-phosphocholine, 1,2-diarachidonoyl-sn-glycero-3-phosphocholine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine, 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (ME 16.0 PE), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinolenoyl-sn-glycero-3-phosphoethanolamine, 1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine, 1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DOPG), and sphingomyelin,
wherein the PEG-lipid comprises one or more selected from 1,2-dimyristoyl-sn-glycerol methoxypolyethylene glycol (PEG-DMG), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)] (PEG-DSPE), PEG-disteryl glycerol (PEG-DSG), PEG-dipalmetoleyl, PEG-dioleyl, PEG-distearyl, PEG-diacylglycamide (PEG-DAG), PEG-dipalmitoyl phosphatidylethanolamine (PEG-DPPE), and PEG-1,2-dimyristyloxlpropyl-3-amine (PEG-c-DMA),
wherein the composition comprises a Tris (tris(hydroxymethyl)aminomethane) buffer and sucrose, and
wherein less than about 10% of the mRNA is in the form of an ionizable lipid-polynucleotide adduct impurity, as measured by reverse phase ion pair high performance liquid chromatography (RP-IP HPLC).
2 . The method of claim 1 , wherein the ionizable lipid is
3 . The method of claim 2 , wherein less than about 5% of the mRNA in the composition is in the form of the ionizable lipid-polynucleotide adduct impurity.
4 . The method of claim 2 , wherein less than about 1% of the mRNA in the composition is in the form of the ionizable lipid-polynucleotide adduct impurity.
5 . The method of claim 2 , wherein an amount of the ionizable lipid-polynucleotide adduct impurity in the composition increases at an average rate of less than about 2% per day when the composition is stored at a temperature of about 25° C. or below.
6 . The method of claim 2 , wherein an amount of the ionizable lipid-polynucleotide adduct impurity in the composition increases at an average rate of less than about 0.5% per day when the composition is stored at a temperature of about 5° C. or below.
7 . The method of claim 2 , wherein an amount of the ionizable lipid-polynucleotide adduct impurity in the composition increases at an average rate of less than about 0.5% per day when the composition is stored at a refrigerated temperature.
8 . The method of claim 7 , wherein the refrigerated temperature is about 5° C.
9 . The method of claim 2 , wherein the ionizable lipid-polynucleotide adduct impurity comprises an aldehyde-mRNA adduct impurity.
10 . The method of claim 2 , wherein an amount of lipid aldehydes in the composition is less than about 50 ppm.
11 . The method of claim 2 , wherein the composition comprises a molar ratio of 20-60% ionizable lipid, 5-25% phospholipid, 25-55% cholesterol, and 0.5-15% PEG lipid, based on the lipid components.
12 . The method of claim 1 , wherein the ionizable lipid is
13 . The method of claim 12 , wherein less than about 5% of the mRNA in the composition is in the form of the ionizable lipid-polynucleotide adduct impurity.
14 . The method of claim 12 , wherein less than about 1% of the mRNA in the composition is in the form of the ionizable lipid-polynucleotide adduct impurity.
15 . The method of claim 12 , wherein an amount of the ionizable lipid-polynucleotide adduct impurity in the composition increases at an average rate of less than about 2% per day when the composition is stored at a temperature of about 25° C. or below.
16 . The method of claim 12 , wherein an amount of the ionizable lipid-polynucleotide adduct impurity in the composition increases at an average rate of less than about 0.5% per day when the composition is stored at a temperature of about 5° C. or below.
17 . The method of claim 12 , wherein an amount of the ionizable lipid-polynucleotide adduct impurity in the composition increases at an average rate of less than about 0.5% per day when the composition is stored at a refrigerated temperature.
18 . The method of claim 17 , wherein the refrigerated temperature is about 5° C.
19 . The method of claim 12 , wherein the ionizable lipid-polynucleotide adduct impurity comprises an aldehyde-mRNA adduct impurity.
20 . The method of claim 12 , wherein an amount of lipid aldehydes in the composition is less than about 50 ppm.
21 . The method of claim 12 , wherein the composition comprises a molar ratio of 20-60% ionizable lipid, 5-25% phospholipid, 25-55% cholesterol, and 0.5-15% PEG lipid, based on the lipid components.
22 . The method of claim 1 , wherein the phospholipid comprises one or more selected from distearoylphosphatidylcholine (DSPC) and dipalmitoylphosphatidylcholine (DPPC), and wherein the PEG-lipid comprises one or more selected from 1,2-dimyristoyl-rac-glycerol-methoxy (polyethylene glycol)-2000 (DMG-PEG2000) and 1,2-distearoyl-sn-glycerol-methoxy (polyethylene glycol)-2000 (DSPE-PEG2000).
Assignments (2)
SECURITY INTEREST
Recorded Nov 19, 2025
From: MODERNATX, INC.
To: ARES CAPITAL CORPORATION, AS AGENT
Reel/Frame 073634/0354 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 19, 2024
From: PARKER, MEREDITH; GYAWALI, DIPENDRA; MERCER, GREGORY JOHN; HUA, SERENUS; BUTORA, GABOR
To: MODERNATX, INC.
Reel/Frame 066488/0463 →
Continuity (7)
Continuation
17974286
· Oct 26, 2022
Provisional Application
63191655
· May 21, 2021
Provisional Application
63182428
· Apr 30, 2021
Provisional Application
63151523
· Feb 19, 2021
References Cited (400)
US 6652886B2
· Alm et al.
· 2003
[cited by applicant]
US 6696038B1
· Mahala et al.
· 2004
[cited by applicant]
US 7268120B1
· Horton et al.
· 2007
[cited by applicant]
US 7371404B2
· Panzner et al.
· 2008
[cited by applicant]
US 7943168B2
· Schlesinger et al.
· 2011
[cited by applicant]
US 8058069B2
· Yaworski et al.
· 2011
[cited by applicant]
US 8158601B2
· Chen et al.
· 2012
[cited by applicant]
US 8420123B2
· Troiano et al.
· 2013
[cited by applicant]
US 8440614B2
· Castor
· 2013
[cited by applicant]
US 8450298B2
· Mahon et al.
· 2013
[cited by applicant]
US 8460696B2
· Slobodkin et al.
· 2013
[cited by applicant]
US 8460709B2
· Ausbor et al.
· 2013
[cited by applicant]
US 8568784B2
· Lillard et al.
· 2013
[cited by applicant]
US 8569256B2
· Heyes et al.
· 2013
[cited by applicant]
US 8580297B2
· Essler et al.
· 2013
[cited by applicant]
US 8642076B2
· Manobarao et al.
· 2014
[cited by applicant]
US 8652487B2
· Maldonado
· 2014
[cited by applicant]
US 8691750B2
· Constien et al.
· 2014
[cited by applicant]
US 8697098B2
· Perumal et al.
· 2014
[cited by applicant]
US 8709483B2
· Farokhzad et al.
· 2014
[cited by applicant]
US 8710200B2
· Schrum et al.
· 2014
[cited by applicant]
US 8715736B2
· Sachdeva et al.
· 2014
[cited by applicant]
US 8734832B2
· O'Hagan et al.
· 2014
[cited by applicant]
US 8734846B2
· Ali et al.
· 2014
[cited by applicant]
US 8754062B2
· De Fougerolles et al.
· 2014
[cited by applicant]
US 8822663B2
· Schurum et al.
· 2014
[cited by applicant]
US 8999380B2
· Bancel et al.
· 2015
[cited by applicant]
US 9221891B2
· Bancel et al.
· 2015
[cited by applicant]
US 9303079B2
· Bancel et al.
· 2016
[cited by applicant]
US 9464124B2
· Bancel et al.
· 2016
[cited by applicant]
US 9512456B2
· Wang et al.
· 2016
[cited by applicant]
US 9597380B2
· Chakraborty et al.
· 2017
[cited by applicant]
US 9868691B2
· Benenato
· 2018
[cited by applicant]
US 9872900B2
· Ciaramella et al.
· 2018
[cited by applicant]
US 20030073619A1
· Mahato et al.
· 2003
[cited by applicant]
US 20030092633A1
· Kisich et al.
· 2003
[cited by applicant]
US 20040142474A1
· Mahala
· 2004
[cited by applicant]
US 20050143336A1
· Ramesh et al.
· 2005
[cited by applicant]
US 20060172003A1
· Meers et al.
· 2006
[cited by applicant]
US 20090042825A1
· Matar et al.
· 2009
[cited by applicant]
US 20110200582A1
· Baryza
· 2011
[cited by applicant]
US 20110244026A1
· Guild et al.
· 2011
[cited by applicant]
US 20120021042A1
· Panzaer et al.
· 2012
[cited by applicant]
US 20120157500A1
· Weikang
· 2012
[cited by applicant]
US 20120178702A1
· Huang
· 2012
[cited by applicant]
US 20130017223A1
· Hope et al.
· 2013
[cited by applicant]
US 20130031583A1
· Shi et al.
· 2013
[cited by applicant]
US 20130102034A1
· Schnu et al.
· 2013
[cited by applicant]
US 20130122104A1
· Yaworski et al.
· 2013
[cited by applicant]
US 20130123338A1
· Heyes et al.
· 2013
[cited by applicant]
US 20130156845A1
· Manoharan et al.
· 2013
[cited by applicant]
US 20130171241A1
· Geall
· 2013
[cited by applicant]
US 20130183353A1
· Jain et al.
· 2013
[cited by applicant]
US 20130189351A1
· Geall
· 2013
[cited by applicant]
US 20130202684A1
· Geall et al.
· 2013
[cited by applicant]
US 20130236550A1
· Ausborn et al.
· 2013
[cited by applicant]
US 20130243867A1
· Mabapatra et al.
· 2013
[cited by applicant]
US 20130245107A1
· de Fougerolles et al.
· 2013
[cited by applicant]
US 20130266640A1
· de Fougerolles et al.
· 2013
[cited by applicant]
US 20130295043A1
· Kallen et al.
· 2013
[cited by applicant]
US 20140045913A1
· Kuboyama et al.
· 2014
[cited by applicant]
US 20140065172A1
· Echeverri et al.
· 2014
[cited by applicant]
US 20140065204A1
· Hayes et al.
· 2014
[cited by applicant]
US 20140113137A1
· Podobinski et al.
· 2014
[cited by applicant]
US 20140121263A1
· Fitzgerald et al.
· 2014
[cited by applicant]
US 20140141070A1
· Geall et al.
· 2014
[cited by applicant]
US 20140141089A1
· Liang
· 2014
[cited by applicant]
US 20140148502A1
· Bancel et al.
· 2014
[cited by applicant]
US 20140193482A1
· Bancel et al.
· 2014
[cited by applicant]
US 20140206752A1
· Afeyan et al.
· 2014
[cited by applicant]
US 20140206753A1
· Guild et al.
· 2014
[cited by applicant]
US 20140378538A1
· Bancel et al.
· 2014
[cited by applicant]
US 20150141499A1
· Bancel et al.
· 2015
[cited by applicant]
US 20150307542A1
· Roy et al.
· 2015
[cited by applicant]
US 20150315541A1
· Bancel et al.
· 2015
[cited by applicant]
US 20160032273A1
· Skalnokt et al.
· 2016
[cited by applicant]
US 20160271272A1
· Bancel et al.
· 2016
[cited by applicant]
US 20170202979A1
· Chakraborty et al.
· 2017
[cited by applicant]
US 20180000953A1
· Almarsson et al.
· 2018
[cited by applicant]
US 20180237849A1
· Thompson
· 2018
[cited by applicant]
US 20180243225A1
· Caramella
· 2018
[cited by applicant]
US 20180271970A1
· Ciarurnella et al.
· 2018
[cited by applicant]
US 20180273977A1
· Mousavi
· 2018
[cited by applicant]
US 20180274009A1
· Marquardt et al.
· 2018
[cited by applicant]
US 20180289792A1
· Ciaramella et al.
· 2018
[cited by applicant]
US 20180303929A1
· Ciaramella et al.
· 2018
[cited by applicant]
US 20180311336A1
· Ciaramella et al.
· 2018
[cited by applicant]
CA 3128215
· 2020
[cited by applicant]
CN 102813929
· 2012
[cited by applicant]
CN 104644555
· 2015
[cited by applicant]
EP 2073848
· 2013
[cited by applicant]
EP 1404860
· 2013
[cited by applicant]
WO WO1999014346
· 1999
[cited by applicant]
WO WO1999052503
· 1999
[cited by applicant]
WO WO2005034979
· 2005
[cited by applicant]
WO WO2008042973
· 2008
[cited by applicant]
WO WO2009024599
· 2009
[cited by applicant]
WO WO2009127060
· 2009
[cited by applicant]
WO WO2010042877
· 2010
[cited by applicant]
WO WO2010054406
· 2010
[cited by applicant]
WO WO2010088537
· 2010
[cited by applicant]
WO WO2010129709
· 2010
[cited by applicant]
WO WO2010144710
· 2010
[cited by applicant]
WO WO201101710
· 2011
[cited by applicant]
WO WO2011068810
· 2011
[cited by applicant]
WO WO2012006376
· 2012
[cited by applicant]
WO WO2012006378
· 2012
[cited by applicant]
WO WO2012030901
· 2012
[cited by applicant]
WO WO2012031043
· 2012
[cited by applicant]
WO WO2012031046
· 2012
[cited by applicant]
WO WO2012129483
· 2012
[cited by applicant]
WO WO2012149252
· 2012
[cited by applicant]
WO WO2012149393
· 2012
[cited by applicant]
WO WO2012153338
· 2012
[cited by applicant]
WO WO2013006825
· 2013
[cited by applicant]
WO WO2013006834
· 2013
[cited by applicant]
WO WO2013006837
· 2013
[cited by applicant]
WO WO2013006838
· 2013
[cited by applicant]
WO WO2013006842
· 2013
[cited by applicant]
WO WO2013033563
· 2013
[cited by applicant]
WO WO2013049328
· 2013
[cited by applicant]
WO WO2013052167
· 2013
[cited by applicant]
WO WO2013056132
· 2013
[cited by applicant]
WO WO2013057715
· 2013
[cited by applicant]
WO WO2013059496
· 2013
[cited by applicant]
WO WO2013059922
· 2013
[cited by applicant]
WO WO2013064911
· 2013
[cited by applicant]
WO WO2013066903
· 2013
[cited by applicant]
WO WO2013067537
· 2013
[cited by applicant]
WO WO2013086322
· 2013
[cited by applicant]
WO WO2013086373
· 2013
[cited by applicant]
WO WO2013086526
· 2013
[cited by applicant]
WO WO2013087083
· 2013
[cited by applicant]
WO WO2013090186
· 2013
[cited by applicant]
WO WO2013093648
· 2013
[cited by applicant]
WO WO2013135359
· 2013
[cited by applicant]
WO WO2013143555
· 2013
[cited by applicant]
WO WO2013143683
· 2013
[cited by applicant]
WO WO2013148541
· 2013
[cited by applicant]
WO WO2013149141
· 2013
[cited by applicant]
WO WO2013158127
· 2013
[cited by applicant]
WO WO2013158579
· 2013
[cited by applicant]
WO WO2013166498
· 2013
[cited by applicant]
WO WO2013173693
· 2013
[cited by applicant]
WO WO2013185069
· 2013
[cited by applicant]
WO WO2014008334
· 2014
[cited by applicant]
WO WO2014026284
· 2014
[cited by applicant]
WO WO2014028487
· 2014
[cited by applicant]
WO WO2014054026
· 2014
[cited by applicant]
WO WO2014071072
· 2014
[cited by applicant]
WO WO2014072997
· 2014
[cited by applicant]
WO WO2014081507
· 2014
[cited by applicant]
WO WO2014144196
· 2014
[cited by applicant]
WO WO2014152774
· 2014
[cited by applicant]
WO WO2014160243
· 2014
[cited by applicant]
WO WO2014172045
· 2014
[cited by applicant]
WO WO2014182661
· 2014
[cited by applicant]
WO WO2014210356
· 2014
[cited by applicant]
WO WO2015095340
· 2015
[cited by applicant]
WO WO2015130584
· 2015
[cited by applicant]
WO WO2015148247
· 2015
[cited by applicant]
WO WO2015164674
· 2015
[cited by applicant]
WO WO2015164786
· 2015
[cited by applicant]
WO WO2016037053
· 2016
[cited by applicant]
WO WO2016118724
· 2016
[cited by applicant]
WO WO2016118725
· 2016
[cited by applicant]
WO WO2016164762
· 2016
[cited by applicant]
WO WO2016201377
· 2016
[cited by applicant]
WO WO2017013463
· 2017
[cited by applicant]
WO WO2017015457
· 2017
[cited by applicant]
WO WO2017019935
· 2017
[cited by applicant]
WO WO2017020026
· 2017
[cited by applicant]
WO WO2017031232
· 2017
[cited by applicant]
WO WO2017031241
· 2017
[cited by applicant]
WO WO2017049245
· 2017
[cited by applicant]
WO WO2017062513
· 2017
[cited by applicant]
WO WO2017066789
· 2017
[cited by applicant]
WO WO2017070601
· 2017
[cited by applicant]
WO WO2017070613
· 2017
[cited by applicant]
WO WO2017070616
· 2017
[cited by applicant]
WO WO2017070618
· 2017
[cited by applicant]
WO WO2017070620
· 2017
[cited by applicant]
WO WO2017070622
· 2017
[cited by applicant]
WO WO2017070623
· 2017
[cited by applicant]
WO WO2017070624
· 2017
[cited by applicant]
WO WO2017070626
· 2017
[cited by applicant]
WO WO2017099823
· 2017
[cited by applicant]
WO WO2017201333
· 2017
[cited by applicant]
WO WO2017201340
· 2017
[cited by applicant]
WO WO2017201342
· 2017
[cited by applicant]
WO WO2017201347
· 2017
[cited by applicant]
WO WO2018053209
· 2018
[cited by applicant]
WO WO2018075980
· 2018
[cited by applicant]
WO WO2018089540
· 2018
[cited by applicant]
WO WO2018081459
· 2018
[cited by applicant]
WO WO2018081462
· 2018
[cited by applicant]
WO WO2018089831
· 2018
[cited by applicant]
WO WO2018107088
· 2018
[cited by applicant]
WO WO2018111967
· 2018
[cited by applicant]
WO WO2018144082
· 2018
[cited by applicant]
WO WO2018144778
· 2018
[cited by applicant]
WO WO2018151816
· 2018
[cited by applicant]
WO WO2018170245
· 2018
[cited by applicant]
WO WO2018170256
· 2018
[cited by applicant]
WO WO2018170260
· 2018
[cited by applicant]
WO WO2018170270
· 2018
[cited by applicant]
WO WO2018170347
· 2018
[cited by applicant]
WO WO2018175783
· 2018
[cited by applicant]
WO WO2018187590
· 2018
[cited by applicant]
WO WO2018200737
· 2018
[cited by applicant]
WO WO2018232355
· 2018
[cited by applicant]
WO WO2019036670
· 2019
[cited by applicant]
WO WO2019036682
· 2019
[cited by applicant]
WO WO2019036683
· 2019
[cited by applicant]
WO WO2019036685
· 2019
[cited by applicant]
WO WO2019226650
· 2019
[cited by applicant]
WO WO2021159040
· 2021
[cited by applicant]
WO WO2021159130A2
· 2021
[cited by applicant]
WO WO2021211343A1
· 2021
[cited by applicant]
WO WO2013148186
· 2021
[cited by applicant]
WO WO2022101486A1
· 2022
[cited by applicant]
Rutkowski et al (Clin. Exp. Allergy, vol. 51, pp. 770-777 (2021)) (Year: 2021).
[cited by examiner]
U.S. Appl. No. 18/277,346 (Year: 2023).
[cited by examiner]
Azarani, A. et al., “RNA analysis by ion-pair reversed-phase high performance liquid chromatography,” Nucleic Acids Res 29, E7 (2001).
[cited by applicant]
Baden et al., “Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine,” N. Engl. J. Med 384, 403-416 (2021).
[cited by applicant]
Baumeister et al., “Continuous flow synthesis of amine oxides by oxidation of tertiary amines,” React. Chem. Eng. 4, 1270-1276 (2019).
[cited by applicant]
Crommelin et al., “Addressing the cold reality of mRNA vaccine stability,” J. Pharm. Sci. 110, 997-1001 (2021).
[cited by applicant]
Cullis et al., “Lipid nanoparticle systems for enabling gene therapies,” Mol. Ther. 25, 1467-1475 (2017).
[cited by applicant]
Extended European Search Report for EP 22153335.9 dated Jul. 18, 2022 (8 pages).
[cited by applicant]
Fenton et al., “Bioinspired alkenyl amino alcohol ionizable lipid materials for highly potent in vivo mRNA delivery,” Adv. Mater. 28, 2939-2943 (2016).
[cited by applicant]
Foreign Search Report on PCT PCT/US2022/016902 Dtd Jul. 25, 2022.
[cited by applicant]
Foreign Search Report on US Dtd Jul. 18, 2022.
[cited by applicant]
Garaycoechea et al., “Alcohol and endogenous aldehydes damage chromosomes and mutate stem cells,” Nature 553, 171-177 (2018).
[cited by applicant]
Gilleron et al., “Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape,” Nat. Biotechnol. 31, 638-646 (2013).
[cited by applicant]
Gomez-Aguado et al., “Nanomedicines to deliver mRNA: state of the art and future perspectives,” Nanomaterials 10, 364 (2020).
[cited by applicant]
Guevara et al., “Advances in lipid nanoparticles for mRNA-based cancer immunotherapy,” Front Chem. 8, 589959 (2020).
[cited by applicant]
Heyes et al., “Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids,” J. Control Release 107, 276-287 (2005).
[cited by applicant]
Houseley et al., “The many pathways of RNA degradation,” Cell 136, 763-776 (2009).
[cited by applicant]
Huang et al., “Enhanced delivery of siRNA to retinal ganglion cells by intravitreal lipid nanoparticles of positive charge,” Mol. Pharm. 18, 377-385 (2021).
[cited by applicant]
International Search Report and Written Opinion for PCT/US2022/016902 mailed Jul. 25, 2022. (12 pages).
[cited by applicant]
Kanavarioti, A. “HPLC methods for purity evaluation of man-made singlestranded RNAs,” Sci. Rep. 9, 1019 (2019).
[cited by applicant]
Khurana et al., “Role of nanotechnology behind the success of mRNA vaccines for COVID-19,” Nano Today 38, 101142 (2021).
[cited by applicant]
Kim et al., “Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver,” Sci. Adv. 7, eabf4398 (2021).
[cited by applicant]
Kok et al., “N-demethylation of N-methyl alkaloids with ferrocene,” Bioorg. Med Chem. Lett. 20, 4499-4502 (2010).
[cited by applicant]
Kowalski et al., “Delivering the messenger: advances in technologies for therapeutic mRNA delivery,” Mol. Ther. 27, 710-728 (2019).
[cited by applicant]
Levin et al., “Combining ion pairing agents for enhanced analysis of oligonucleotide therapeutics by reversed phase-ion pairing ultra performance liquid chromatography (UPLC),” J. Chromatogr. B Anal. Technol. Biomed. Li…
[cited by applicant]
Liu, S et al., “Membrane-destabilizing ionizable phospholipids for organselective mRNA delivery and CRISPR-Cas gene editing,” Nat. Mater. 20, 701-710 (2021).
[cited by applicant]
Nelson et al. “Impact of mRNA chemistry and manufacturing process on innate immune activation,” Sci. Adv. 6, eaaz6893 (2020).
[cited by applicant]
Packer et al., “A novel mechanism for the loss of mRNA activity in lipid nanoparticle delivery systems,” Nature Comm. 12:6777 (Nov. 2021).
[cited by applicant]
Pogocki et al. “Chemical stability of nucleic acid-derived drugs,” J. Pharm. Sci. 89, 443-456 (2000).
[cited by applicant]
Polack et al., “Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine,” N. Engl. J. Med 383, 2603-2615 (2020).
[cited by applicant]
Prieve et al., “Targeted mRNA therapy for ornithine transcarbamylase deficiency,” Mol. Ther. 26, 801-813 (2018).
[cited by applicant]
Reichmuth et al., “mRNA vaccine delivery using lipid nanoparticles,” Ther. Deliv. 7, 319-334 (2016).
[cited by applicant]
Sabnis et al., “A novel amino lipid series for mRNA delivery: improved endosomal escape and sustained pharmacology and safety in non-human primates,” Mol. Ther. 26, 1509-1519 (2018).
[cited by applicant]
Takeshita et al., “In vitro DNA/RNA adductomics to confirm DNA damage caused by benzo[a]pyrene in the Hep G2 cell line,” Front Chem. 7, 491 (2019).
[cited by applicant]
Wang et al., “AN1616: SEC-MALS Method for Characterizing mRNA Biophysical Attributes,” WYATT Technology, https://wyattfiles.s3-us-west-2.amazonaws.com/literature/app-notes/sec-malsbiopolymers/AN1616-SEC-MALS-method-for-…
[cited by applicant]
Wu et al., “Nanoparticle-mediated cytoplasmic delivery of messenger RNA vaccines: challenges and future perspectives,” Pharm. Res. 38, 473-478 (2021).
[cited by applicant]
Yang et al., “Factors affecting DNA damage caused by lipid hydroperoxides and aldehydes,” Free Radic. Biol. Med 20, 225-236 (1996).
[cited by applicant]
Zhang al., “Helper lipid structure influences protein adsorption and delivery of lipid nanoparticles to spleen and liver,” Biomater. Sci. 9, 1449-1463 (2021).
[cited by applicant]
PCT/US2016/000129, dated Mar, 6, 2017, Invitation to Pay Additional Fees.
[cited by applicant]
PCT/US2016/000129, dated May 22, 2017, International Search Report and Written Opinion.
[cited by applicant]
PCT/US2016/000129, dated Dec. 11. 2017. International Search Report and Written Opinion.
[cited by applicant]
Abu Lila et al., Application of polyglycerol coating to plasmid DNA lipoplex for the evasion of the accelerated blood clearance phenomenon in nucleic acid delivery. J Pharm Sci. Feb. 2014;103(2):557-66. doi: 10.1002/ps.…
[cited by applicant]
Abu Lila et al., Use of polyglycerol (PG), instead of polyethylene glycol (PEG), prevents induction of the accelerated blood clearance phenomenon against long-circulating liposomes upon repeated administration. Int J Ph…
[cited by applicant]
Akinc et al., Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms, Mol Ther. 2009 17:872-879.
[cited by applicant]
Anderson. D.M. et al., Stability of mRNA/cationic lipid lipoplexes in human and rat cerebrospinal fluid: methods and evidence for nonviral mRNA gene delivery to the central nervous system. Hum Gene Ther. Feb. 10, 2003;1…
[cited by applicant]
Andreakos et al., Amphoteric liposomes enable systemic antigen-presenting cell-directed delivery of CD40 antisense and are therapeutically effective in experimental arthntis. Arthritis Rheum. Apr. 2009:60(4):994-1005. d…
[cited by applicant]
Andries, O. et al., Comparison of the gene transfer efficiency of mRNA/GL67 and pDNA/GL67 complexes in respiratory cells. Mal Pharmaceutics. 2012; 9: 2136-2145.
[cited by applicant]
Bag, J., Rec of normal protein synthesis in heat-shocked chicken myotubes by liposome-mediated transfer of mRNAs. Can. J. Biochem. Cell Biol. 1985; 63(3): 231-235.
[cited by applicant]
Bellivean, N.M., et al., Microfluidic synthesis of highly potent limit-size lipid nanoparticles for in vivo delivery of siRNA. mol Ther Nucleic Acids. Aug. 2012; 1(8): e37.
[cited by applicant]
Bettinger, T. et al., Peptide-mediated RNA delivery: a novel approach for enhanced transfection of primary and post-mitotic cells. Nucleic Acids Res. Sep. 15, 2001;29(18):3882-91.
[cited by applicant]
Bogers et al., Potent immune responses in rheus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion.J Infect Dis. Mar. 15, 2015;211(6):947-5…
[cited by applicant]
Bolhassani et al. , Improvement of Different Vaccine Delivery Systems for Cancer Therapy, Molecular Cancer, Biomed Central, London, GB, 2011, vol. 10, No. 3, pp. 1-20.
[cited by applicant]
Chamberlain et al., Recurrent lymphomatous meningitis treated with intra-CSF rituximab and liposomal ara-C. J Neurooncol. Feb. 2009;91(3):271-7. doi: 10.1007/s11060-008-9707-1. Epub Sep. 27, 2008.
[cited by applicant]
Chen, D., et al., Rapid discovery of potent siRNA-containing lipid nanoparticles enabled by controlled microfluidic formulation. J Am Chem Soc. 2012; 134: 6948-6951.
[cited by applicant]
Corazzelli et al., Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxonibicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moder…
[cited by applicant]
Can ct al., Preparation and characterization of poly(DL-lactide-co- glycolide) nanoparticles for siRNA delivery. International Journal of Pharmaceutics 390 (2010) 70-75.
[cited by applicant]
Dahlman et al., In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight. Nature Nanotechnology, 2014, No. vol.#, pp. 1-8.
[cited by applicant]
Delchanty Peptides for Specific Intracellular Delivery and Targeting of Nanoparticles: Implications for Developing Nanoparticle-Mediated Drug Delivery, Future Science, Therapeutic Delivery, 2010, vol. 1, No. 3, pp. 411-…
[cited by applicant]
Delmas et al., Encapsulation and Release Behavior from Lipid Nanoparticles: Model Study with Nile Red Fluorophore. J. Colloid Sci. Biotechnol. 2012;1:16-25.
[cited by applicant]
Felgner, Cationic lipid/poly nucleotide condensates for in vitro and in vivo polynucleotide delivery-the cylofectins. J. of Liposome Research. 1993: 3(1): 3-16.
[cited by applicant]
Felgner, et al., Lipofection: a highly efficient, lipid-mediated DNA—transfection procedure. Proc Natl Acad Sci U SA. Nov. 1987;84(2 1):7413-7.
[cited by applicant]
Felgner, Particulate systems and polymers for in vitro and in vivo delivery of polynucleotides. Adv. Drug Delivery Rev. 1990; 5(3): 163-187.
[cited by applicant]
Flecion et al., Self-replicative RNA vaccines elicit protection against influenza a virus, respiratory syncytial virus, and a fickborne encephalitis virus. J Infect Dis. May 1, 2001;183(9):1395-8. Epub Mar. 30, 2001.
[cited by applicant]
Ocall et al., Nonviral delivery of self-amplifying RNA vaccines Proc Natl Acad Sci US A. Sep. 4. 2012;109(36):14604-9. doi:10. 1073/pnas.1209367109. Epub Aug. 20, 2012.
[cited by applicant]
Hashimoto et al., Relationship between the concentration anti-polyethylene glycol (PEG) immunoglobulin M (IgM) and the intensity of the accelerated blood clearance (ABC) phenomenon against PEGylated liposomes in mice. B…
[cited by applicant]
He et al. Synthesis and Separation of Diastercomers of Ribonucleoside 5′-(alpha-P-Borano) triphosphates. J Org Chem. Aug. 21, 1998;63(17):5769-5773
[cited by applicant]
Hecker et al., Non-Viral DNA and mRNA Gene Delivery to the CNS Pre-Operatively for Neuroprotection and Following Neurotrauma. Molecular Therapy. 2004; 9, S258-S258.
[cited by applicant]
Juliano et al., Cell-targeting and cell-penetrating peptides for delivery of therapeutic and imaging agents. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnolog May/Jun. 2009; 1(3): 324-335
[cited by applicant]
Kallen et al., A development that may evolve into a revolution in medicine; mRNA as the basis for novel, nucleotide-based vaccines and drugs. Ther Adv Vaccines. Jan, 2014:2(1):10-31, doi: 10,1177/2051013613508729
[cited by applicant]
Kallen et al., A novel, disruptive vaccination technology: self-adjuvanted RNActive(RTM) vaccines. Hum Vaccin Immunother. Oct. 2013:9(10):2263-76. doi: 10.4161/hv.25181. Epub Jun. 4, 2013. Review.
[cited by applicant]
Kanapathipillai et al., Nanoparticle targeting of anti-cancer drugs that alter intracellular signaling or influence the tumor microenvironment, Adv. Drug Deliv. Rev. (2014), pp. 1-12.
[cited by applicant]
Kariko et al., Generating the optimal mRNA for thempy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res. vol. 39, No. 21, Nov. 1, 2…
[cited by applicant]
Kariko et al., In vivo protein expression from mRNA delivered into adult rat brain. J. of Neuroscience Methods. Jan, 2001, 105(1); 77-86.
[cited by applicant]
Kanko et al., Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability, Molecular Therapy, Nature Publishing Group, GB, vol. 16, No. 1…
[cited by applicant]
Kariko et al., Phosphate-enhanced transfection of cationic lipid-complexed mRNA and plasmid DNA. Biochim Biophys Acta. Mar. 2, 1998;1369(2):320-34.
[cited by applicant]
Kauffman et al., Efficacy and immunogenicity of unmodified and psendouridine-modified mRNA delivered systemically with lipid nanoparticles in vivo. Biomaterials. Dec. 2016;109:78-87. doi: 10.1016/j.biomaterials.2016.09.…
[cited by applicant]
Kcown et al., Methods for Introducing DNA into Mammalian Cells. Methods in Enzymology, 1990, 185:527-37.
[cited by applicant]
Kirpotin et al., Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 2006; 66: 6732-67 40.
[cited by applicant]
Kozielski et al., Bioreducible Cationic Polymer-Based Nanoparticles for Efficient and Environmentally Triggered Cytoplasmic siRNA Delivery to Primary Human Brain Cancer Cells, ACS Nano. 2014, vol. 8,‘No. 4’.pp. 3232-332…
[cited by applicant]
Krause et al., Prevention of the hemodynamic effects of iopromide-carrying liposomes in rats and pigs. Invest Radio!. Aug. 2000;35(8):493-503.
[cited by applicant]
Lai et al., Mucus-penetrating nanoparticles for drug and gene delivery to mucosa! tissues. Ady Drug Deliv Rev. Feb. 27, 61(2): 158-171.
[cited by applicant]
Lai et al., Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. PNAS, Jan. 30, 2007; 104(5): 1482-1487.
[cited by applicant]
Lee et al., Lipidi Nanoparticle siRNA Systems for Silencing the Ardtrogen Receptor in Human Prostate Cancer in Vivo, International Journal of Cancer, 2012, vol. 131, pp. 781-790.
[cited by applicant]
Lehto et al., Cell-penetrating peptides for the delivery of nucleic acids. Expert Opin. Drug Deliv. Jul. 2012; 9(7): 823-836.
[cited by applicant]
Lewis, Dynamic Polyconjugates (DPC) Technology: An elegant solution to the siRNA delivery problem. Arrowhead Research Corp (NASDAQ: ARWR). Nov. 2011.
[cited by applicant]
Li et al., Overcoming obstacles to develop effective and safe siRNA therapeutics. Expert Opin Biol Thex. May 2009; 9(5): 609-19.
[cited by applicant]
Li et al., Preparation and gene delivery of alkaline amino acids-based cationic liposomes. Arch Pharm Res. Jul. 2008:31(7):924-31. Epub Aug. 14, 2008.
[cited by applicant]
Lian et al., Trends and developments in liposome dig delivery systems. J Pharm Sci. Jun. 2001;90(6):667-80.
[cited by applicant]
Lopez-Berestein et al., Treatment of systemic fungal infections with liposomal amphotericin B. Arch Intern Med. Nov. 1989:149(11):2533-6.
[cited by applicant]
Maclachlan, Lipid Nanoparticle-mediated delivery of messenger RNA. Presentation. 1st International mRNA Health Conference. Tubingen, Germany, Oct. 24, 2013, http://files.shareholder.com/downloads/ABEA-50QJTB/2628241206x…
[cited by applicant]
Madden et al., Systemic delivery of mRNA therapeutics using lipid nanoparticles (LNP): improved potency for novel LNP and influence of route of administration on protein expression. 2nd International mRNA Health Confere…
[cited by applicant]
Magee et al., Marked stimulation oflymphocyte-mediated attack on tumor cells by target-directed liposomes containing immune RNA, Cancer Res., 1978, 38(4):1173-6.
[cited by applicant]
Malone et al., Cationic liposome-mediated RNA transfection. Proc Natl Acad Sci USA, Aug. 1989;86(16):6077-81.
[cited by applicant]
Marina et al., Dose escalation and pharmacokinetics of pegyled liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study. Clin Cancer Res. Feb. 2002;8(2):413-8.
[cited by applicant]
Martinon et al., Induction of vins- cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. EurJ Immunol. Jul. 1993:23(7):1719-22.
[cited by applicant]
Maurer et al., Spontaneous entrapment of polynucleotides upon electrostatic interaction with ethanol-destabilized cationic liposomes. Biophys J. May 2001; 80(5): 2310-2326.
[cited by applicant]
Midoux et al., Lipid-based mRNA vaccine delivery systems. Expert Rev Vaccines, Feb. 2015:14(2):221-34 doi: 10.1586/14760584. 2015.986104. Epub Dec. 26, 2014. Review.
[cited by applicant]
Mishra et al., Improved leishmanicidal effect of phosphorothioate antisense oligonucleotides by LDL-mediated delivery. Biochim Biophys Acta Nov. 7. 1995:1264(2):229-37.
[cited by applicant]
Mockey et al., mRNA-based cancer vacc evention of B16 melanoma progression and metastasis by systemic injection of MARTI mRNA histidylated hpopolyplexes, Cancer Gene Therapy, 2007, 14, pp. 802-814.
[cited by applicant]
Nair et al., Soluble proteins delivered to dendritic cells via pH-sensitive liposomes induce primary cytotoxic T lymphocyte responses in virto. J Exp Med. Feb. 1, 1992;175(2):609-12.
[cited by applicant]
Oja et al., Doxorubicin entrapped within liposome-associated anti-gens results in a selective inhibition of the antibody response to the linked antigen. Biochim Biophy Acta. Sep. 29, 2000;1468(1-2):31-40.
[cited by applicant]
Oster et al. Compscitive study of DNA encapsulation into PLGA microparticles using modified double emulsion methods and spray drying techniques. Journal of Microencapsulation, May 2005; 22(3): 235-244.
[cited by applicant]
Parker et al., Targeting of Polyelectrolyte RNA Complexes to Cell Surface Integrias as an Efficient, Cytoplasmic Transfection Mechanism, Journal of Bioactive and Compatible Polymers, Jul. 2002, pp. 1-10.
[cited by applicant]
Pollard et al., Type 1 IFN counteracts the induction of antigen- specific immune responses by lipid-based delivery of mRNA vaccines. Mol Ther. Jan. 2013: 21 (1): 251-259.
[cited by applicant]
Popov et al., Multivalent rituximab lipid nanoparticles as improved lymphoma therapies: indirect mechanisms of action and in vivo activity nNanomedicine (Lond). Nov. 2011;6(9): 1575-91. doi: 10.2217/ nnm. 11.50 Epub Oct…
[cited by applicant]